Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

NET 3Gastrointestinal 3Endocrine 3CNS 1

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 3Somatostatin Receptor-positive Neuroendocrine Tumor 1Somatostatin Receptor-positive GEP-NET 1Pheochromocytoma 1Paraganglioma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Advanced Neuroendocrine Neoplasm 1

Interventions

lutetium Lu 177 dotatate 3Octreotide 3pasireotide 2lanreotide 2amino-acid, glucose, and electrolyte solution 2Everolimus 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2famitinib 1copper dotatate CU-64 1arginyllysine 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1PM 01183 1Oxaliplatin 1Lutetium-177 1Lutetium 1Leucovorin 1Irinotecan 1Folfox protocol 1Fluorouracil 1E-7386 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Gastro-enteropancreatic neuroendocrine tumor × lutetium Lu 177 dotatate × Clear all
NCT04727723 2026-05-04

REAL-LU

Novartis

Completed
164 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡